IDEAYA Biosciences (NASDAQ:IDYA) Issues Earnings Results

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82), Zacks reports. The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million.

IDEAYA Biosciences Trading Up 1.1 %

Shares of IDYA stock traded up $0.22 during trading on Wednesday, hitting $20.66. The company's stock had a trading volume of 866,030 shares, compared to its average volume of 886,098. The business has a fifty day moving average of $23.94 and a 200-day moving average of $29.44. The company has a market cap of $1.79 billion, a PE ratio of -6.26 and a beta of 0.82. IDEAYA Biosciences has a 52 week low of $19.96 and a 52 week high of $47.72.

Analysts Set New Price Targets

IDYA has been the topic of a number of analyst reports. Leerink Partnrs lowered shares of IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 5th. Wedbush reissued an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. UBS Group started coverage on IDEAYA Biosciences in a research note on Thursday, October 24th. They set a "buy" rating and a $50.00 target price for the company. Oppenheimer reissued an "outperform" rating and issued a $53.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Finally, Leerink Partners downgraded shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $53.58.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.